JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(2):90-93 | DOI: 10.36290/csf.2025.012

Current pharmacotheraupeutical options of lower urinary tract symptoms

Marcela Fontana
Urologická klinika 2. LF UK, Praha

Lower urinary tract symptoms (LUTS) represent a wide unit with multifactorial etiology, and therefore, treatment is not uniform. In most patients with LUTS, pharmacotherapy is an effective option for managing these symptoms, thereby improving the quality of life. We have medications from various drug classes available, which can be effectively combined to achieve the best therapeutic outcome. The following text provides an overview of the current pharmacotherapy for LUTS.nce-based medicine principles are essential when searching for and critically evaluating information use in pregnancy.

Keywords: lower urinary tract symtoms, LUTS, pharmacotherapy, α-1 adrenoreceptor antagonists, 5α-reductase inhibitors, muscarinic receptor antagonists, beta-3 agonists, phosphodiesterase 5 inhibitors.

Accepted: May 28, 2025; Published: June 18, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fontana M. Current pharmacotheraupeutical options of lower urinary tract symptoms. Čes. slov. farm. 2025;74(2):90-93. doi: 10.36290/csf.2025.012.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • PDF will be unlocked 18.6.2026

    References

    1. Cornu J-NL, Gravas S, Gacci M, et al. Management of Non-neurogenic Male LUTS. EAU Guidelines. Arnhem: EAU Guidelines Office; 2025. Available from: https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts.
    2. Harding C, Lapitan MC, Arlandis S, et al. Non-neurogenic Female LUTS. EAU Guidelines. Arnhem: EAU Guidelines Office; 2025. Dostupné také z: https://uroweb.org/guidelines/non-neurogenic-female-luts.
    3. Šolínová J. Farmaceutická péče při samoléčení běžných urologických potíží. Čes. slov. Farm. 2024;1(73):48-56. Go to original source... Go to PubMed...
    4. Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004 Dec;64(6):1081-8. Go to original source... Go to PubMed...
    5. SPC jednotlivých léků, dostupné z Databáze léků. Státní ústav pro kontrolu léčiv [Internet], SÚKL: ©2010 [cit. 15.01.2025]. Available from: https://www.sukl.cz/.
    6. Roehrborn CG, Siami P, Barkin J, et al. CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010 Jan;57(1):123-31. Go to original source... Go to PubMed...
    7. McConnell JD, Roehrborn CG, Bautista OM, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec18;349(25):2387-98. Go to original source... Go to PubMed...
    8. Roehrborn CG, Oyarzabal Perez I, Roos EP, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116(3):450-9. Go to original source... Go to PubMed...
    9. Krhut J, Ryšánková K, Zachoval R. Nežádoucí účinky anticholinergik užívaných v léčbě hyperaktivního močového měchýře na centrální nervový systém. Ces Urol. 2024; 28(3):133-140. Go to original source...
    10. Kakizaki H, Lee KS, Yamamoto O, et al. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). Eur Urol Focus. 2020;6(4):729-737. Go to original source... Go to PubMed...
    11. Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS). J Urol. 2020;203(6):1163-1171. Go to original source... Go to PubMed...
    12. Drlík P. Nykturie - současné možnosti terapie. Urolog. pro Praxi. 2010;11(4):176-179.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.